Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is an interesting stock at present. Now trading with a market value of 6.11B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For VRX, the company currently has 1.21 billion of cash on the books, which is offset by 353 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 42.33 billion in total assets, balanced by 38.34 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
Valeant Pharmaceuticals International, Inc. (VRX) saw 878 million in free cash flow last quarter, representing a quarterly net change in cash of 668 million. Perhaps most importantly where cash movements are concerned, the company saw about 916 million in net operating cash flow.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Revenue Growth Potential
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 2.11 billion in total revenues. That represents a quarterly year/year change in revenues of -0.11 in sequential terms, the VRX saw sales decline by -0.12.
But what about the bottom line? After all, that’s what really matters in the end. Valeant Pharmaceuticals International, Inc. (VRX) is intriguing when broken down to its core data. The cost of selling goods last quarter was 1.23 billion, yielding a gross basic income of 878 million. For shareholders, given the total diluted outstanding shares of 350.5 million, this means overall earnings per share of 1.79. Note, this compares with a consensus analyst forecast of 0.96 in earnings per share for its next fiscal quarterly report.
Is Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Valuation Attractive
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 3.85 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 4.49. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Valeant Pharmaceuticals International, Inc..